1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 31 pages

Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014’, provides an overview of the Mochida Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mochida Pharmaceutical Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Mochida Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Mochida Pharmaceutical Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Mochida Pharmaceutical Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate Mochida Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Mochida Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Mochida Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Mochida Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mochida Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Mochida Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014
Table of Contents

Mochida Pharmaceutical Co., Ltd. Snapshot 5
Mochida Pharmaceutical Co., Ltd. Overview 5
Key Information 5
Key Facts 5
Mochida Pharmaceutical Co., Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Mochida Pharmaceutical Co., Ltd. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Mochida Pharmaceutical Co., Ltd. - Pipeline Products Glance 12
Mochida Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Mochida Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Mochida Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Mochida Pharmaceutical Co., Ltd. - Drug Profiles 16
dienogest 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
mesalamine ER 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
icosapent ethyl 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
etanercept biosimilar 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Mochida Pharmaceutical Co., Ltd. - Pipeline Analysis 22
Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Target 22
Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 23
Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 24
Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 25
Mochida Pharmaceutical Co., Ltd. - Recent Pipeline Updates 26
Mochida Pharmaceutical Co., Ltd. - Dormant Projects 27
Mochida Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 28
Discontinued Pipeline Product Profiles 28
ulinastatin 28
Mochida Pharmaceutical Co., Ltd. - Locations And Subsidiaries 29
Head Office 29
Other Locations and Subsidiaries 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables

Mochida Pharmaceutical Co., Ltd., Key Information 5
Mochida Pharmaceutical Co., Ltd., Key Facts 5
Mochida Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 7
Mochida Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 8
Mochida Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 9
Mochida Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 10
Mochida Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 11
Mochida Pharmaceutical Co., Ltd. - Phase III, 2014 12
Mochida Pharmaceutical Co., Ltd. - Phase II, 2014 13
Mochida Pharmaceutical Co., Ltd. - Phase I, 2014 14
Mochida Pharmaceutical Co., Ltd. - Preclinical, 2014 15
Mochida Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 22
Mochida Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 23
Mochida Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 24
Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 25
Mochida Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 26
Mochida Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 27
Mochida Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 28
Mochida Pharmaceutical Co., Ltd., Subsidiaries 29

List of Figures

Mochida Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2014 7
Mochida Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 8
Mochida Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 9
Mochida Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 10
Mochida Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2014 22
Mochida Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014 23
Mochida Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014 24
Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Acyl CoA Desaturase ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.